Literature DB >> 8034027

Complete reconstitution of conjugation and subsequent degradation of the tumor suppressor protein p53 by purified components of the ubiquitin proteolytic system.

D Shkedy1, H Gonen, B Bercovich, A Ciechanover.   

Abstract

The wild-type tumor suppressor protein p53 is a short-lived protein that plays important roles in regulation of cell cycle, differentiation, and survival. Mutations that inactivate or alter the tumor suppressor activity of the protein seem to be the most common genetic change in human cancer and are frequently associated with changes in its stability. The ubiquitin system has been implicated in the degradation of p53 both in vivo and in vitro. A mutant cell line that harbors a thermolabile ubiquitin-activating enzyme, E1, fails to degrade p53 at the nonpermissive temperature. Studies in cell-free extracts have shown that covalent attachment of ubiquitin to the protein requires the three conjugating enzymes: E1, a novel species of ubiquitin-carrier protein (ubiquitin-conjugating enzyme; UBC),E2-F1, and an ubiquitin-protein ligase, E3. Recognition of p53 by the ligase is facilitated by formation of a complex between the protein and the human papillomavirus (HPV) oncoprotein E6. Therefore, the ligase has been designated E6-associated protein (E6-AP). However, these in vitro studies have not demonstrated that the conjugates serve as essential intermediates in the proteolytic process. In fact, in many cases, conjugation of ubiquitin to the target protein does not signal its degradation. Thus, it is essential to demonstrate that p53-ubiquitin adducts serve as essential proteolytic intermediates and are recognized and degraded by the 26S protease complex, the proteolytic arm of the ubiquitin pathway. In this study, we demonstrate that conjugates of p53 generated in the presence of purified, E1, E2, E6-AP, E6, ubiquitin and ATP, are specifically recognized by the 26S protease complex and degraded. In contrast, unconjugated p53 remains stable. The ability to reconstitute the system from purified components will enable detailed analysis of the recognition process and the structural motifs involved in targeting the protein for degradation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8034027     DOI: 10.1016/0014-5793(94)00582-6

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  11 in total

1.  Involvement of the DNA repair protein hHR23 in p53 degradation.

Authors:  Sandra Glockzin; Francois-Xavier Ogi; Arnd Hengstermann; Martin Scheffner; Christine Blattner
Journal:  Mol Cell Biol       Date:  2003-12       Impact factor: 4.272

2.  Characterization of Puma-dependent and Puma-independent neuronal cell death pathways following prolonged proteasomal inhibition.

Authors:  Liam P Tuffy; Caoimhín G Concannon; Beatrice D'Orsi; Matthew A King; Ina Woods; Heinrich J Huber; Manus W Ward; Jochen H M Prehn
Journal:  Mol Cell Biol       Date:  2010-10-04       Impact factor: 4.272

3.  Proteolysis by calpains: a possible contribution to degradation of p53.

Authors:  M Pariat; S Carillo; M Molinari; C Salvat; L Debüssche; L Bracco; J Milner; M Piechaczyk
Journal:  Mol Cell Biol       Date:  1997-05       Impact factor: 4.272

4.  Stepwise multipolyubiquitination of p53 by the E6AP-E6 ubiquitin ligase complex.

Authors:  Yuji Masuda; Yasushi Saeki; Naoko Arai; Hidehiko Kawai; Iwao Kukimoto; Keiji Tanaka; Chikahide Masutani
Journal:  J Biol Chem       Date:  2019-09-06       Impact factor: 5.157

Review 5.  Roles of proteasomes in cell growth.

Authors:  A Ichihara; K Tanaka
Journal:  Mol Biol Rep       Date:  1995       Impact factor: 2.316

Review 6.  The 20S/26S proteasomal pathway of protein degradation in muscle tissue.

Authors:  B Dahlmann; L Kuehn
Journal:  Mol Biol Rep       Date:  1995       Impact factor: 2.316

7.  Degradation of the proto-oncogene product c-Fos by the ubiquitin proteolytic system in vivo and in vitro: identification and characterization of the conjugating enzymes.

Authors:  I Stancovski; H Gonen; A Orian; A L Schwartz; A Ciechanover
Journal:  Mol Cell Biol       Date:  1995-12       Impact factor: 4.272

Review 8.  Targeting the ubiquitin-proteasome system for cancer therapy.

Authors:  Min Shen; Sara Schmitt; Daniela Buac; Q Ping Dou
Journal:  Expert Opin Ther Targets       Date:  2013-07-04       Impact factor: 6.902

9.  An essential ubiquitin-conjugating enzyme with tissue and developmental specificity in th nematode Caenorhabditis elegans.

Authors:  M Zhen; J E Schein; D L Baillie; E P Candido
Journal:  EMBO J       Date:  1996-07-01       Impact factor: 11.598

10.  Elucidating the catalytic subunit composition of distinct proteasome subtypes: a crosslinking approach employing bifunctional activity-based probes.

Authors:  Kimberly Cornish Carmony; Lalit Kumar Sharma; Do-Min Lee; Ji Eun Park; Wooin Lee; Kyung-Bo Kim
Journal:  Chembiochem       Date:  2014-12-04       Impact factor: 3.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.